Maternal and neonatal outcomes in extra hepatic portal vein obstruction: Our experience

Smitha Elizabeth Jacob¹, Ravi Shankar², Anoop John³, C.E. Eapen³, Bijesh Yadav⁴, Swati Rathore¹

¹Departments of Obstetrics and Gynaecology, ²Cardiac Thoracic Surgery, ³Gastroenterology, ⁴Biostatistics, Christian Medical College & Hospital, Vellore, Tamil Nadu, India

Abstract

Background: Women with Extra hepatic portal vein obstruction (EHPVO) are mostly young and belong to Asian countries. In the Indian subcontinent, 20–30% variceal bleeds are caused by EHPVO. Hence pregnancy is a concern in such patients. The objective of this study is to observe the maternal and neonatal outcomes in women with EHPVO. Materials and Method: Extra hepatic portal vein obstruction was studied retrospectively in 28 pregnancies in 20 women from Jan 2011 to July 2018 at a tertiary hospital in South India and the pregnancy outcomes were observed during this period. Institutional Review Board approval obtained. Results: The mean age of the women was 24.3 years and the mean age of diagnosis was 18.5 years. Splenomegaly, thrombocytopenia and anaemia were seen in 22 (78.5%), 17 (60.7%) and 8 (28.5%) of pregnancies, respectively. Rate of abortions and preterm deliveries were 2 (7.1%, n=28) and 10 (35.7%, n=28). There was one stillbirth (3.6%) in the study group. EHPVO was diagnosed in 25 (89.3%) women prenatally in our series. During pregnancy only one woman had variceal bleed, which was managed conservatively. Blood and blood product transfusion was required in 7 (25%) of women and there was no maternal mortality. Conclusion: Pregnancies in EHPVO have good maternal and neonatal outcomes, provided they are taken care of by a multidisciplinary approach in a tertiary care centre.

Keywords: EHPVO, EST, EVL, maternal outcome, portal hypertension, pregnancy
Multidisciplinary approach to pre-conceptional counselling, detailed evaluation and antenatal care is important for optimisation and good obstetric outcome.

**Materials and Methods**

This is a retrospective observational study of all women with extra hepatic portal vein obstruction who were pregnant and took treatment in Christian Medical College, Vellore from 01/01/2011 to 01/07/2018. This study was approved by research committee and ethics committee of CMC Institutional review board (IRB) approval number is 11500[Retro]

The data was collected and analysed from outpatient and inpatient records. The maternal factors considered are duration of disease, index presentation, gestational age, interventions required for EHPVO prenatally and during pregnancy, complications of upper gastrointestinal bleed, spontaneous bacterial peritonitis and ascites. Other factors considered were, the mode of delivery (lower segment caesarean section, vaginal delivery, instrumental delivery), neonatal outcomes, postpartum complications such as haemorrhage, ICU admission, requirement of blood and blood products.

**Case definition**

EHPVO: Asian Pacific Association for Study of Liver diseases defines EHPVO as a vascular disorder of liver, characterised by obliteration of extra-hepatic portion of portal-vein. This condition may or may not be linked with involvement of intra-hepatic portal vein radicles, splenic or superior mesenteric veins.\(^8\)

Thrombocytopenia: In this study thrombocytopenia is taken as platelet value less than 100,000 platelets per cubic mm of blood.

Preterm: Birth before 37 completed weeks of gestation.

Abortion: Loss of pregnancy prior to 24 weeks of gestation.

Stillbirth: Birth after 24 weeks of pregnancy-with no signs of life.

Depressed at birth: Included in the study as APGAR ≤7 at 1 minute of-life

Early neonatal death: Death of a live born within first week-of life.

Good outcome: is defined as pregnancy beyond 28 completed weeks with live born baby with no complications requiring ICU care for mother.

Postpartum haemorrhage: Blood loss more than 500 ml in vaginal delivery and >1000 ml in LSCS within first 24 hours of delivery.

Intrauterine growth restriction (IUGR): If estimated weight of foetus is below 10th percentile for its gestational age.

Anaemia: Haemoglobin level less than 11 gm/dl (Mild anaemia- 9–10.9 gm/dl, moderate anaemia 7–8.9 gm/dl, severe anaemia : less than 7 gm/dl).

**Results**

Total of the 28 pregnancies with EHPVO were retrospectively studied.

The duration from diagnosis was less than five years for 17 (60.7%) of the women. The index presentation was variceal bleed in 14 (50%) of women. In 9 (32%) of the women it was diagnosed incidentally during ultrasonographic examination and blood investigation. In 25 (89.3%) women the diagnosis of EHPVO was made prior to pregnancy, as seen in Table 1. Two women were diagnosed during pregnancy and one postpartum. The mean age of diagnosis was 18.5 years. While most of the women were of 24.3 years of age. Out of these 11 were primigravidae.

Both obstetric and neonatal outcomes and complications related to portal vein hypertension are mentioned in detail.

**Obstetric outcomes**

Among 28 pregnancies, there were two abortions (7.1%), one IUD which occurred at 36 weeks. LSCS was required in 14 (50%) patients, 12 (42.8%) patients were delivered vaginally. All LSCS were done for obstetric reasons. One patient who underwent LSCS had PPH. Blood or blood products were required in 7 (25%) of women as tabulated in Table 2. Four women required ICU care.

**Neonatal outcomes**

Totally, 25 (89.3%) out of 28 pregnancies were live births. Preterm deliveries were seen in 10 (35.7%, \(n = 28\)) of the study population. Birth weight was <2.5 kg in 10 (35.7%, \(n = 28\)), NICU admission in 10 (40%) out of 25 live births. APGAR ≤7 at 1 minute of birth was seen in 3 (12%) out of 25 live births.

**Portal hypertension related complications**

Of the 28 pregnancies, one woman underwent primary EVL elsewhere during antenatal period, and one woman had variceal bleeding which was managed conservatively. Prenatally, portal hypertension related complications of variceal bleeding was index presentation in (14) 50% of the patients. Ascites and jaundice were seen in three and one women respectively; however, none of them had renal complications or encephalopathy.

Totally, 14 women required specific treatment modalities before pregnancy. Endoscopic variceal ligation (EVL) in 5 (17.8%), endoscopic sclerotherapy (EST) in 2 (7.1%), 4 (14.3%) had both EST and EVL. Three women (10.8%) underwent shunt surgery of which one underwent splenectomy as well. 19 (67.8%) of the women were on medical management with Propranolol.
There was splenomegaly in 22 (78.5%) of patients and associated thrombocytopenia was seen in 17 (60.7%) patients. Varying degrees of anaemia was found in 28.5% of patients.

### Discussion

Considering all patients with portal hypertension (PHT), EHPVO is the cause of PHT in one third of them. It constitutes 30% of variceal bleed in developing countries and nearly 5-10% in the west[8]. The etiological origin in children is mainly intra-abdominal infection or umbilical sepsis or catheterization and congenital defects related. In adults it is often occult and underlying prothrombotic states are frequently reported in west than in Asian patients, though the data are inadequate.[7] Other factors imposed are intra-abdominal inflammation and trauma. In adults, EHPVO presentation may be acute or chronic, the differentiation may be difficult.

In acute scenario they may report with febrile illness, associated with abdominal pain and in chronic patients, the presentation is variceal bleeding and hypersplenism. Other manifestations are ascites and jaundice. Portal biliopathy is seen in 80% of the patients but most of the patients are asymptomatic.[8] In Indian population inherited thrombophilia are not very frequent-basis of portal vein thrombosis.[6,8] Ascites is seen in 13–21% of the patients. The study by Keepanasseril et al. in south India showed variceal bleeding complicating 25% of pregnancies in women with non-cirrhotic PHT.[9] However, in this study, EHPVO-related complications of variceal bleed as index presentation was seen...
in 50% of the patients, but during pregnancy only one patient had variceal bleeding which was managed conservatively and one patient had primary EVL done elsewhere. There were three patients with ascites and one with jaundice. Splenomegaly was observed in 78.5% of the patients, of which associated thrombocytopenia was seen in 60.7%. There was no EHPVO-related renal dysfunction or hepatic encephalopathy. The study by Mandal et al. found majority of the patients to be having anaemia (70.8%). In this study, 28.3% of the patients were found to be anemic.

Patients with EHPVO generally have no stigmata of liver disease. Since liver function is preserved, the prognosis is better when compared to patients with cirrhotic liver disease. Long-term studies show almost no mortality post endotherapy. Pregnancy in women with liver cirrhosis has high maternal and foetal morbidity. Mortality can be as high as 50% in pregnant women with liver cirrhosis compared to 2–6% in non–cirrhotic.

There is limited data on pregnancy outcomes with EHPVO. In pregnant women from developing countries, portal hypertension is frequently due to viral and autoimmune-related cirrhosis. The physiological changes in pregnancy resulting in increased blood flow which predispose these patients for enhanced risk from variceal bleed. Figure 1 shows the physiological changes aggravating variceal bleed.

Variceal bleed is the most dreaded complication. Oesophageal varices are seen in 90% and gastric varices are seen in 31–44% cases. In the Indian population, approximately one third of variceal bleed is caused by EHPVO, but does not lead to mortality. The risk is higher in patients with larger varices, undiagnosed, un-optimised patients, previous history of bleeding, severe liver disease, coagulopathy and endoscopic red signs. This study looks at the obstetric and neonatal outcome in patients with EHPVO. Table 3 is a tabulation of various studies of EHPVO in pregnancy.

Prenatally diagnosed and treated patients have nearly nil chances of variceal bleed. In this study prenatal diagnosis of EHPVO was made in 89.3% of the patients. Prior to pregnancy, EVL or EST or both was required in 39.3% of women. There were two women requiring shunt surgery of which one had splenectomy also. Although EVL and EST both are regarded safe in pregnancy, Baveno V-consensus workshop recommends EVL for acute variceal bleed. Thrombocytopenia was seen in 17 (60.7%) patients. Study by Kilambi et al. showed that total platelet count ≤53,500 cells/mm$^3$ independently predicted significantly high portal pressure.

Abortion rate was 23.8% in the study by Subbiah et al. In our study, abortions were seen in 7.1% of the women although history of previous abortion was observed in 39.2% of the women.

Preterm deliveries were seen in 14–19% of the women [refer Table 3]. Totally, 35.7% of the women were delivered before 37 weeks of gestation of which only 3 (10.7%) were less than 32 weeks gestation. 10 (35.7%, n = 25) babies had birth weight <2.5 kg. Intruterine growth restriction was seen in 9 (34.6%, n = 26) of babies. 19 (67.8%) of the women in the study group were on medical management with Propranolol which is FDA category C drug. Though concerns of growth restriction, cardiac anomalies, etc., have been found with beta blockers, the recent studies have shown them to be safe in pregnancy. In this study comparing women with anaemia to women with normal haemoglobin, the rates of IUGR were 42.8 vs 31.6%. Also comparing IUGR in women who were on propranolol and those who were not, the rates of IUGR were 23.5 vs 55.55% [Table 4]. Thus, IUGR was not significantly increased in anaemic women or women on treatment with propranolol. INASL-FOGSI statement, recommends continuation of Propranolol in pregnancy. It is safe to continue during breastfeeding as well. Study by Mandal et al. showed that the perinatal morbidity and mortality associated with prematurity and less birth weight was higher when the diagnosis was made in antenatal period. When prenatally diagnosed, the outcomes were better. In our study 25 patients were diagnosed to have EHPVO prenatally, 2 antenatally and

![Figure 1: Physiological changes aggravating variceal bleed in pregnancy](image)

**Table 3: Various studies on EHPVO in pregnancy**

| Preganacies | Abortion% | Preterm | Still birth | SGA | Thrombocytopenia | PPH | Maternal Mortality (n) |
|------------|-----------|---------|------------|-----|-----------------|-----|-----------------------|
| Subbaiah et al. | 21/12 | 23.8 | 18.7 | 0 | 12.5 | 61.9 | 0 |
| Aggarwal et al. (EHPVO patients) | 23/12 | 17.4 | 10.5 | 15.8 | 5.3 | NA | NA |
| D Mandal et al. | 41/24 | 4.87 | 14.6 | 2.56 | 10.25 | 20.8 | 7.3 | 1 |
only one patient was diagnosed postpartum. There was only one still birth in this study.

12 (42.8%) women were delivered vaginally of which 2 (7.1%) were instrumental delivery. Instrumentation to cut short second stage of labour was required in only one patient. Induction of labour was required in 7 patients and spontaneous onset of labour was seen in 6 patients. The indications of LSCS were for obstetric reasons [Table 5]. Of the patients who had LSCS, 78.6% had subarachnoid block and 21.4% had general anaesthesia. None of the patients had variceal bleed in labour. Postpartum 4 patients required ICU admission. The reasons for ICU admission was not related to worsening of liver disease.

Blood and/or blood products were used in 7 (25%) of women. Three patients required pre-delivery transfusion for low haemoglobin. Preoperative correction of bleeding parameters was required in 3 patients [Table 6]. There was one patient with postpartum haemorrhage requiring transfusion. Maternal mortality is nil to <1% in the studies listed above. There was no maternal mortality in our study group. Good outcome (pregnancy beyond 28 completed weeks with live born baby with no complications requiring ICU care for mother) was seen in 71.4% women.

| Table 4: Comparing rates of IUGR in women with anaemia and on Propranolol |
|-----------------------------|------------------|---|
| n (Excluding abortions)     | IUGR  |
| Women with anaemia          | 7     | 3 |
| No anaemia                  | 9     | 5 |
| Women on propranolol        | 7     | 3 |
| Not on propranolol          | 19    | 6 |

| Table 5: Miscellaneous |
|------------------------|
| Indications for LSCS††  |
| Deteriorating maternal condition |
| Chorioamnionitis with ARDS¶  |
| Severe pre eclampsia/HELLP** |
| Cellulitis with sepsis |
| Previous LSCS not willing for VBAC†† |
| Abnormal dopplers |
| Category II NRFS‡‡ |
| Failed induction |
| Previous uterine perforation |
| SPE‡ with unfavourable cervix |

| Table 6: Indications for blood transfusion |
|------------------------------------------|
| Indications for blood transfusion        |
| Pre delivery/termination low haemoglobin |
| PPH*                                     |
| Preoperative deranged bleeding parameters (HELLP, Cellulitis with sepsis) |
| Postoperative deranged bleeding parameters (HELLP) |

Italian Association for the Study of the Liver (AISF) recommends that in chronic cases with stable and nonprogressive disease pattern, pregnancy can be planned.[21]

It is important to know the complications and the importance of multidisciplinary approach so that timely referral can be made not only in the antenatal period but also prenatally for risk stratification, optimisation and better outcome.

**Conclusion**

Disease optimisation is of prime importance in EHPVO. Under optimised conditions, the feto-maternal outcome with EHPVO is good. Anaemia should be corrected to prevent adverse outcomes with variceal bleed or postpartum haemorrhage. Prenatally, complete investigations to rule out low platelet counts, LFT, endoscopy for detection of GI varices should be done and the disease condition should be optimised by medical and surgical management of portal hypertension. Splenectomy or shunt surgery should be done when indicated. Vaginal delivery is preferred and LSCS is required only for obstetric indications. Management is better by multidisciplinary approach during the pregnancy and postpartum period in a tertiary care centre.

**Key points**

1. Normal physiological changes of pregnancy worsen portal hypertension.
2. However, the risk of variceal bleed is low in optimised conditions.
3. Prenatal and antenatal identification, risk stratification and disease optimisation is important for better maternal and neonatal outcome.
4. Antenatal management should be by a multidisciplinary approach in a tertiary care centre.
5. Blood and blood products should be kept ready for delivery.
6. Vaginal delivery is preferred and LSCS is for obstetric reasons only.
7. Non-selective beta blockers like Propranolol are safe in antenatal and lactating period.
8. Maternal mortality is nil to low, but management should be under vigilant look out from pre conceptional to postnatal period.

**Acknowledgements**

The authors would like to thank the medical records department for help in data collection and the guidance from Gastroenterology department.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.
References

1. Wani ZA, Bhat RA, Bhadoria AS, Maiwall R. Extrahepatic portal vein obstruction and portal vein thrombosis in special situations: Need for a new classification. Saudi J Gastroenterol Saudi J Gastroenterol 2015;21:129-38.

2. Poddar U, Borkar V. Management of extra hepatic portal venous obstruction (EHPVO): Current strategies. Trop Gastroenterol 2011;32:94-102.

3. Hanif FM, Soomro GB, Akhund SN, Luck NH, Laeeq SM, Abbas Z, et al. Clinical presentation of extrahepatic portal vein obstruction: 10-year experience at a tertiary care hospital in Pakistan. J Transl Intern Med 2015;3:74-8.

4. Khanna R, Sarin SK. Non-cirrhotic portal hypertension-Diagnosis and management. J Hepatol 2014;60:421-41.

5. Weiss B, Shteyer E, Vivante A, Berkowitz D, Reif S, Weizman Z, et al. Etiology and long-term outcome of extrahepatic portal vein obstruction in children. World J Gastroenterol 2010;16:4968-72.

6. Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, et al. Consensus on extra-hepatic portal vein obstruction. Liver Int 2006;26:512‑9.

7. Jain P, Nijhawan S. Portal vein thrombosis: Etiology and clinical outcome of cirrhosis and malignancy-related non-cirrhotic, non-tumoral extrahepatic portal venous obstruction. World J Gastroenterol 2007;13:5288-9.

8. Chawla YK, Bodh V. Portal vein thrombosis. J Clin Exp Hepatol 2015;5:22-40.

9. Keepanasseril A, Gupta A, Ramesh D, Kothandaraman K, Jeganathan YS, Maurya DK. Maternal-fetal outcome in pregnancies complicated with non-cirrhotic portal hypertension: Experience from a Tertiary Centre in South India. Hepatol Int 2020;14:842-9.

10. Aggarwal N, Negi N, Aggarwal A, Bodh V, Dhiman RK. Pregnancy with portal hypertension. J Clin Exp Hepatol 2014;4:163-71.

11. Tolunay HE, Aydin M, Cin N, Boza B, Dulger AC, Yildizhan R. Maternal and fetal outcomes of pregnant women with hepatic cirrhosis. Gastroenterol Res Pract 2020;2020:5819819. doi: 10.1155/2020/5819819.

12. Westbrook RH, Dusheiko G, Williamson C. Pregnancy and liver disease. J Hepatol 2016;64:933-45.

13. Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation 2014;130:1003-8.

14. Mandal D, Dattaray C, Sarkar R, Mandal S, Choudhary A, Maity TK. Is pregnancy safe with extrahepatic portal vein obstruction? An analysis. Singapore Med J 2012;53:676-80.

15. de Franchis R. Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010;53:762-8.

16. Kilambi R, Singh AN, Madhusudhan KS, Pal S, Saxena R, Shalimar, et al. Portal hypertension and hypersplenism in extrahepatic portal venous obstruction: Are they related? Indian J Gastroenterol 2018;37:202-8.

17. Subbaiah M, Kumar S, Roy KK, Sharma JR, Singh N. Extrahepatic portal-vein obstruction in pregnancy. Taiwan J Obstet Gynecol 2015;54:394-7.

18. Duan L, Ng A, Chen W, Spencer HT, Nguyen J, Shen AY-J, et al. β-blocker exposure in pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med 2017;177:885.

19. Duan L, Ng A, Chen W, Spencer HT, Lee M-S. Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens 2018;20:1603-9.

20. Infant and Young Child Feeding Guidelines, 2016 [Internet]. [cited 2020 Oct 5]. Available from: https://www.indianpediatrics.net/aug2016/aug‑703‑713.htm.

21. Italian Association for the Study of the Liver (AISF), Italian Association for the Study of the Liver AISF. Position paper on liver disease and pregnancy. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2016;48:120-37.